FIELD: medicine.
SUBSTANCE: invention describes using S-amlodipine nicotinate in treating cerebrovascular disorders specified in a group: haemorrhagic stroke, ischemic stroke, including transient global ischemia. A pharmaceutical composition for treating the cerebrovascular disorders contains S-amlodipine nicotinate as an active ingredient in an effective amount of 0.1 mg to 50 mg per a dose, and pharmaceutically acceptable excipients. The composition represents either a tablet, or a solution for injections.
EFFECT: expanding the usage of S-amlodipine nicotinate.
2 cl, 3 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DRUG FOR IMPROVING BLOOD SUPPLY OF ISCHEMIZED BRAIN | 2019 |
|
RU2747202C2 |
| AGENT FOR TREATMENT OF ACUTE AND CHRONIC DISTURBANCES OF CEREBRAL CIRCULATION, INCLUDING STROKE ON BASIS OF HYDROGENATED PYRIDO (4,3-b)INDOLES (VERSIONS), PHARMACOLOGICAL AGENT ON ITS BASIS AND METHOD OF ITS APPLICATION | 2006 |
|
RU2340342C2 |
| SUCCINIC ACID ESTERS OF 5-HYDROXYADAMANTAN-2-ONE, IMPROVING BLOOD SUPPLY TO ISCHEMIC BRAIN | 2017 |
|
RU2658833C1 |
| MEDICINAL COMPOSITION | 2001 |
|
RU2213562C2 |
| PHARMACEUTICAL COMBINATION OF ATORVASTATIN AND NICERGOLIN FOR PREVENTING OR TREATING CEREBROVASCULAR DISEASE | 2011 |
|
RU2481124C1 |
| MAGNESIUM BIS (2-AMINOETHANESULFONIC ACID)-BUTANEDIOATE, WHICH HAS ANTIHYPOXIC, NEUROPROTECTIVE AND HYPOCOAGULANT ACTIVITY | 2017 |
|
RU2671982C1 |
| METHOD FOR TREATMENT OF CEREBROVASCULAR BRAIN DISORDERS (OPTIONS) | 2017 |
|
RU2659674C1 |
| LITHIUM-CONTAINING AGENT TO PREVENT AND TREAT CEREBROVASCULAR DISEASES AND METHOD OF APPLICATION THEREOF | 2008 |
|
RU2367427C1 |
| METHOD FOR PREVENTING CEREBRAL ISCHEMIA | 2018 |
|
RU2696203C1 |
| APPLICATION OF TIMOSAPONIN B-II IN MAKING DRUG OR PRODUCT FOR STROKE PREVENTION AND TREATMENT | 2005 |
|
RU2376993C2 |
